Metabolomic Technology Inc. (MTI) is engaged in using the new science of metabolomics to deliver innovative non-invasive diagnostics to the healthcare market. MTI's flagship product, PolypDx™, is the first and only urine based test with a high sensitivity for detecting adenomatous polyps, the precursor to colorectal cancer, thus providing doctors with a new tool for early screening and detection. In 1000-patient clinical trials in both Canada and China, MTI's PolypDx™ demonstrated higher sensitivity than fecal-based screening tests to detect adenomatous polyps. MTI has partnered with Atlantic Diagnostic Laboratories (ADL), to launch PolypDx™ in the US.
PolypDx™ offers the following advantages:
• Early stage detection: PolypDx™ detects adenomatous polyps, the precursor to colorectal cancer, thereby detecting individuals at risk for colorectal cancer
• High patient compliance: PolypDx™ does not require any unpleasant bowel cleansing preparation, nor unsanitary handling of stool, and does not have any health risks.
• Ease of use: PolypDx™ is fast and simple – just a small urine sample is required
Connect with MTI or ADL if you would like to try PolypDx™ for your patients.
132, 9650 20 Avenue
Edmonton, Alberta T6N 1G1 Canada